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ABSTRACT OF THE THESIS 
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for Novel HIV-Host Interactions 
 
by 
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University of California, Los Angeles, 2018 
Professor Oliver Fregoso, Chair 
 
 Despite impressive advances in the treatment of HIV/AIDS over the past 30 years, there 
is much we do not understand about the HIV life-cycle. While it is well-known that HIV and 
related primate lentiviruses induce an aberrant DNA damage response (DDR) in infected cells, it 
remains unclear exactly how or why this occurs. Working from a curated list of 40 human genes 
associated with DDR, bearing markers of positive selection, and induced by interferon gamma 
signaling, we performed a CRISPR screen for genes that increased or decreased infectivity upon 
knockout in primary CD4+ T cells. The results were analyzed by one-sample T-test to identify 
putative susceptibility and antiviral genes. Subsequently, preliminary experiments were 
conducted to verify the results of the screen via overexpression and shRNA silencing 
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experiments. This study has identified ESPL1, PALB2, and RBBP8 as potential susceptibility 
factors, and POLG, MUTYH, and BRIP1 as potential antiviral factors.     
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Introduction 
Human immunodeficiency virus (HIV) infection, the cause of the deadly AIDS pandemic 
that has claimed the lives of approximately 35 million people since it first emerged in central 
Africa, is no longer the death sentence it once was [1]. In the last 30 years, our ability to 
effectively treat AIDS has increased tremendously through the advent of anti-retroviral therapy 
(ART) [1]. Despite these successes, many details regarding the viral life-cycle remain a mystery. 
For example, it is known that HIV induces a DNA damage response (DDR) in infected cells, yet 
it is unclear exactly how or why this occurs [2]. While the identification of major viral-host 
interactions, such as between the viral glycoprotein gp120 and host co-receptors CD4 and 
CCR5/CXCR4, is assisted by the extreme phenotype effects observed when these interactions 
are blocked, interactions with subtle yet important impacts on the viral life-cycle have evaded 
discovery. These undiscovered interactions may include susceptibility factors, or proteins that 
are co-opted by the virus to ensure or enhance its own replication, as well as antiviral factors, or 
proteins that have some inhibitory effect on viral replication. Until recently, efforts to uncover 
these interactions have been complicated by the inherent difficulty of performing a knockout 
screen without knowing the DNA sequence of the target genes. The development of CRISPR as 
a new genetic tool for the sequence-specific knockout of individual genes has revolutionized the 
field by enabling large screens for host-expressed virus-interacting proteins without the need for 
pre-existing data suggesting their roles in host-pathogen interactions [3]. In this study, we 
applied this CRISPR screening technique in an effort to uncover novel viral-host interactions. 
To identify a list of candidate genes for the CRISPR screen, we first considered genes 
that are involved in the host cell DDR, a process that we know is specifically induced by viral 
proteins, though it remains unclear how this is achieved [2]. Although we do not understand 
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exactly why HIV triggers a DDR in infected cells, the capacity for DDR induction is well 
conserved amongst the primate lentiviruses that constitute HIV’s closest evolutionary relatives 
[4]. This implies that DDR induction plays an important role in the lentiviral life-cycle, as traits 
that do not impart a significant fitness advantage would not survive thousands of years of 
evolutionary drift. The widely-conserved capability of lentiviruses to induce DDR and lack of 
prior knowledge regarding the interactions responsible for this phenomenon make host DDR 
genes a potentially rich source of novel virus-host interacting partners. 
To narrow down this list, we considered the impact that a virus such as HIV has on its 
host over the course of millennia of coevolution. Contrary to popular belief, HIV is not a “new” 
virus - rather, it is a virus that has infected non-human primate populations for thousands of 
years before the start of the AIDS pandemic in the 20th century [5]. The application of 
evolutionary theory to the identification of good candidate genes for the CRISPR screen warrants 
a brief review of the mechanics behind this theory. Most mutations are deleterious or neutral in 
their fitness impact, meaning that random mutations will generally be lost from generation to 
generation through a process known as purifying selection. Deleterious mutations reduce the 
fitness of the mutant organism relative to the “wild-type,” meaning that these mutations will be 
lost due to selective pressure favoring the non-mutant genotype. Neutral mutations, though not 
negatively impacting fitness, will be lost due to subsequent random mutations, as there is no 
selective pressure acting to maintain these mutations. On rare occasions when a mutation does 
provide a fitness advantage, however, the mutation will be conserved over time by the loss of 
fitness that would occur if the mutation were to be reversed. Genes experiencing high rates of 
conserved mutations are said to undergo positive selection, a process by which mutation away 
from the consensus sequence is driven by strong selective pressure. 
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In the context of host-pathogen interactions, instances of positive selection are frequently 
associated with antagonistic cat-and-mouse games between viral and host proteins [6]. When a 
host protein is “hijacked” by a viral protein as part of the viral life-cycle, mutations to the host 
gene that interfere with this hijacking may provide the host organism with a substantial fitness 
advantage. If the frequency of this new “escape” mutation increases sufficiently in the host 
organism population, the virus may respond to this selective pressure by selecting for mutations 
to the antagonizing viral protein that restore the original interaction with its host-expressed 
target. Similarly, a viral protein targeted by the host’s immune response will be driven to mutate 
the sequence recognized by the antiviral protein. Escape mutations in the viral protein will allow 
the virus to circumvent parts of the host immune system, driving mutation of the host antiviral 
protein to re-establish its efficacy. This pattern of positive selection, particularly at potential 
interfaces of interaction between host and viral proteins, allows us to select host genes that show 
high frequencies of positive selection when compared to genes that do not interact with viruses 
[6, 7]. Indeed, signatures of positive selection can be found in many primate genes, each a mark 
of past arms races between primates and their respective lentiviruses [6, 7, 8]. As such, a curated 
list of genes undergoing positive selection in non-human primates provides a good starting point 
to identifying potential viral-host interaction partners in humans.  
We further refined this list by focusing on genes that are also stimulated by or lead to the 
induction of interferon gamma, a key signaling molecule during initiation of a host immune 
response [9, 10]. If DDR genes have an antiviral effect, it is reasonable to expect that they might 
also be activated by or lead to the induction of the most prominent antiviral signaling pathway.  
Having assembled a list of potential susceptibility and antiviral factors, our collaborators 
at UCSF electroporated activated CD4+ T cells from two donors with CRISPR and guide RNAs 
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targeting each gene individually for knockout. Several non-targeting controls (NTC), which are 
CRISPR molecules bearing scrambled guide RNAs, were used as negative controls, whilst the 
co-receptor CXCR4 and known viral integrase cofactor LEDGF were used as positive controls 
for susceptibility [11, 12]. These cells were then infected in triplicate with a CXCR4-tropic, GFP 
reporter virus, at which point GFP fluorescence was measured for each sample at three time-
points over the course of a week post-infection [3]. Since GFP fluorescence in this context 
effectively measures infection and replication, conditions with elevated GFP relative to NTCs 
should represent potential antiviral factors, whilst conditions with decreased GFP relative to 
NTCs should represent potential susceptibility factors. Using a one-sample T-test, we compared 
GFP fluorescence from each individual gene knockout condition to the overall population mean. 
Gene knockouts with T-scores that deviated substantially from the population mean were 
considered to be screen hits. To further evaluate the significance of potential viral-host 
interactions with these gene products, we have begun overexpression and shRNA silencing 
experiments. Overexpression of susceptibility proteins may increase infectivity and replication, 
whilst silencing should reduce infectivity and replication, with opposite results expected for 
similar experiments targeting potential antiviral factors. Through the CRISPR screen and 
preliminary results from overexpression/silencing experiments, we have identified the human 
genes ESPL1, PALB2, and RBBP8 as potential susceptibility factors, and POLG, MUTYH, and 
BRIP1 as potential antiviral factors. 
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Methods 
Evolutionary analysis and IFN screening 
All amino acid sequences were obtained from NCBI genebank database. Subsequent sequence 
alignments of ten to thirty different primates including humans were done in Geneious software 
10.0.5 using the MUSCLE alignment algorithm [https://www.geneious.com, 13]. In order to 
maximize alignment accuracy and to eliminate interference for detection of positive selection, 
alignments were manually edited by removing gaps or sequence discrepancies among the aligned 
sequences. Alignments were analyzed for signatures of positive selection using maximum-
likelihood statistical algorithms in PAML software [14]. Genes displaying signatures of positive 
selection were then cross referenced to a curated literature search for IFN-induced genes (O. 
Fregoso, unpublished). 
CRISPR-mediated gene editing 
CRISPR Cas9 RNP-mediated gene editing was performed in collaboration with the Krogan lab 
(UCSF) as described in Hultquist et al [3]. Briefly, donor CD4+ T cells were isolated from whole 
blood via Ficoll gradient centrifugation from two independent healthy donors and enriched using 
the Easysep CD4+ T-cell enrichment kit (Stemcell Technologies). CD4+ T cells were cultured in 
RPMI and stimulated via anti-CD3 coated plates and soluble anti-CD28 for 48 hours before 
electroporation. Cells were then electroporated with 20uM Cas9 RNP complex in 96-well plate 
format using an Amaxa 4D Nucleofector. Cells were allowed to recover for 30 minutes before 
re-stimulating cells for 24 hours with 10ug/mL soluble anti-CD3 and anti-CD28. After 48 hours 
of cell stimulation and Cas9 RNP targeting, cells were infected with HIV-1 LAI ∆Nef GFP in 
triplicate. Infectivity was measured at days 3, 5, and 7 post-infection by flow cytometry for GFP. 
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Statistical analysis of CRISPR screen results 
Triplicate %GFP+ values were averaged for each guide and the resulting values were compared 
to the population average %GFP+ by one-sample T-test. All statistical analysis was performed 
using Excel software (Microsoft). T-scores from data collected from all guides on days 3, 5, and 
7 for each donor were calculated and the results were plotted as a population distribution using 
Prism software (GraphPad). 
shRNA knockdown and lentivirus production 
shRNA viral production was done according to invitrogen protocol, Improve lentiviral production 
using lipofectamine 3000 reagent. 293T cells were transiently transfected using Lipofectamine 
3000 (invitrogen), pMD2.G envelope plasmid (Addgene), psPAX.2 lentiviral packaging plasmid 
(Addgene), and Mission shRNA pLKO1 plasmids (Sigma) for target gene knockdown. Virus was 
collected 72-hours post-transfection from cell supernatant, filtered through a 0.2µm syringe filter, 
and used immediately to infect 293T cells. 
Analysis of editing efficiency 
Genomic DNA was extracted from edited cells with QuickExtract DNA extraction solution 
(Illumina). Target sequence was amplified with HiFi DNA polymerase (NEB). PCR products were 
sequenced by Sanger sequencing and editing efficiency was calculated by TIDE analysis 
[https://tide.nki.nl/, 15]. 
Overexpression and western blotting 
Overexpression constructs were purchased from the UCLA CNSI MSSR library. When not 
available, genes were amplified from 293T and/or Jurkat cDNA (Superscript II, Invitrogen) using 
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gene-specific primers and cloned into the pcDNA3.1 plasmid through standard cloning techniques. 
Plasmids were transfected into 293T cells with lipofectamine 3000 (Invitrogen). Thirty-six hours 
following transfection, cells were lysed with RIPA buffer and protein expression was analyzed by 
western blotting with the following antibodies: rabbit polyclonal anti-human polymerase gamma 
antibody (Genetex), rabbit polyclonal anti-human MUTYH antibody (Genetex), rabbit polyclonal 
anti-human BRIP1/BACH1 antibody (Bethyl Laboratories) and rabbit polyclonal anti-human 
PALB2 antibody (Bethyl Laboratories). 
Results 
 Virus-host interactions tend to result from targeting of host systems that are directly or 
indirectly connected to the viral life cycle. As such, to screen for potential HIV cofactors and 
restriction factors, we first assembled a list of DDR genes that bear markers of positive selection, 
are stimulated by interferon, or both. Using this list and a recently developed high-throughput 
CRISPR knockout screening method, individual genes were knocked out in CD4+ T cells 
isolated from whole blood provided by two HIV-negative donors and subsequently activated as 
previously described (figure 1) [3]. NTC synthetic guide RNAs were also used to produce 
CRISPR RNPs to control for off-target CRISPR editing. Subsequently, the cells were infected 
with a CXCR4-tropic GFP reporter virus, after which GFP fluorescence was measured for each 
sample on days 3, 5, and 7 post-infection. Post-CRISPR electroporation and HIV infection cell 
viability was estimated by live/dead gating on forward and side scatter during flow cytometric 
analysis. 
While the majority of screened genes were not associated with significant increases or 
decreases in GFP signal (as measured by %GFP+ cells), the deletion of 3 genes was correlated 
with increased signal, while deletion of 5 genes was correlated with decreased GFP signal. This 
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second group included well-established susceptibility factors such as the co-receptor CXCR4 and 
LEDGF, which is required for targeted integration, supporting the legitimacy of this CRISPR 
screening technique. Crucially for the interpretation of this data, the six NTCs included in this 
experiment yielded %GFP+ values that were distributed throughout the overall population of 
%GFP+ values. An ideal control for this CRISPR screen would consist of a scrambled sgRNA 
that is incapable of enabling CRISPR-based gene editing, and would thus produce a %GFP+ 
value that approximates the average value seen in untreated, infected CD4+ T cells. The fact that 
our NTCs were so widely distributed around the population mean %GFP+ value made it difficult 
to analyze the statistical significance of any increase or decrease in %GFP+ cells observed in 
gene knockout samples, as it effectively means that we lack a reliable negative control. This fact, 
in combination with the negative skew of the population of %GFP+ values, led us to assess the 
magnitude of the difference between each individual CRISPR guide GFP result and the overall 
population mean through one-sample T-tests. 
 Upon one-sample T-test analysis, the top and bottom 10% tails of the resulting T-score 
distributions for each donor were considered for potential candidacy (figure 2, figure 3). Genes 
with high scores across multiple guides, multiple data collection timepoints, and in both donors 
were advanced for further screening: putative susceptibility factors ESPL1, PALB2, and RBBP8 
(table 1), as well as putative antiviral factors POLG, MUTYH, and BRIP1 (table 2). 
While this screen allowed us to identify these candidate genes, we next assessed the 
efficiency of the knockout process for each guide. If guides that led to more efficient gene 
knockout were correlated with T-scores that deviated more from the population average, it would 
support our assertion that these genes are restriction or susceptibility factors. On the other hand, 
if the overall knockout efficiency for a high-scoring gene was low, it could mean that a new set 
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of experiments with optimized guide RNAs may produce a stronger phenotype. To estimate the 
efficiency with which each sgRNA caused knockout of the targeted gene, we sequenced DNA 
from each sample and used the tracking indels by decomposition (TIDE) webtool 
[https://tide.nki.nl/, 15]. Provided the sequence of the targeted DNA and that of the sgRNA, 
TIDE is able to calculate an approximate percentage of the overall population of a DNA sample 
that features indels at the targeted site. TIDE analysis revealed a rough correlation between 
editing efficiency and T-score in both donors, as well as the poor editing efficiency seen for 
some scoring genes, such as BRIP1 (table 1, table 2).  
Aside from CRISPR knockout, the effect of each candidate gene on viral replication can 
also be assessed through overexpression and shRNA silencing experiments. To support the 
results of the initial CRISPR screen, overexpression of restriction or susceptibility factors may 
cause a decrease or increase, respectively, in infectivity. Conversely, the silencing of restriction 
or susceptibility factors might cause an increase or decrease, respectively, in infectivity. To 
assess the effects of gene overexpression on viral infectivity, it was first necessary to acquire 
appropriate overexpression constructs. Overexpression constructs were obtained from the UCLA 
CNSI MSSR library or generated from 293T and/or Jurkat cell cDNA. Subsequently, these 
overexpression constructs were used to identify suitable polyclonal antibodies detecting 
candidate gene expression via western blot. Suitable polyclonal antibodies were identified for 
POLG, MUTYH, BRIP1, ESPL1, and PALB2, though no appropriate antibody was found for 
RBBP8 during the course of this study (figure 4). Finally, three pooled shRNA lentiviral vectors 
for each candidate were tested through infection of 293T cells previously transfected with gene 
of interest overexpression vectors, with lysates being used for western blot analysis (figure 5). 
Future infectivity experiments in T cells transfected with overexpression vectors and/or infected 
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with shRNA lentiviruses will give us a clearer picture of the role played by each of our candidate 
genes in HIV infection and replication.        
Discussion 
 This study has, so far, identified several candidates for novel antiviral and HIV-
susceptibility factors. Putative antiviral factors include POLG, or mitochondrial polymerase 
gamma, MUTYH, a human homolog of the Escherichia coli DNA repair factor mutY, and BRIP1, 
or BRCA1-interacting protein. Previous studies have indicated that POLG plays a role in the 
proper function of thymocytes, as inactivating mutation of this gene can cause 
immunodeficiency in humans [16]. It is possible that this gene is a key regulator of successful T 
cell activation, as a recent case report of an infant male heterozygous for a POLG missense 
mutation found that the patient’s T cells had reduced sensitivity to IL-2 stimulation [16]. Further 
research will be necessary in order to determine how this phenotype might be related to 
increased HIV susceptibility. A member of the DNA glycosylase family, MUTYH plays a key 
role in base excision repair, meaning it may directly impact DDR triggered during HIV infection. 
While deletion of MUTYH increased HIV infection efficiency in this study, a previous study 
found that siRNA silencing of MUTYH had the opposite effect, reducing infection efficiency 
[17]. Further experiments will be required to determine the nature of the interaction between 
HIV and MUTYH. While there is a lack of previously published studies evaluating the 
relationship between BRIP1 and the HIV life-cycle, it is well known that the binding partner of 
BRIP1, BRCA1, is a key mediator of double-strand break repair [18, 19]. Previous work has 
shown that BRIP1 is required for functional BRCA1 activity during DDR, a conclusion 
supported by the observation that inactivating mutation of BRIP1 is sufficient to significantly 
increase the risk of breast and ovarian cancer [20, 21]. It is possible that the apparent HIV fitness 
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advantage conferred by induced DDR is decreased by the DSB-resolving activity of BRCA1, and 
thus that BRIP1 indirectly decreases infection efficiency through interaction with BRCA1.  
The putative susceptibility factors identified in this study include ESPL1, or extra spindle 
pole bodies-like 1(also known as separase), PALB2, or partner and localizer of BRCA2, and 
RBBP8, or retinoblastoma binding protein 8 (also known as CtIP). ESPL1 performs a key 
regulatory role during mitosis by cleaving the cohesin Scc1, a protein responsible for preventing 
separation of sister chromatids before the start of anaphase [22]. It is possible that this activity of 
ESPL1 is manipulated by HIV to extend DDR, though this will need to be evaluated in future 
work. PALB2 is necessary for the nuclear localization of BRCA2, where it also enables the 
formation of a BRCA1-PALB2-BRCA2 complex required for homologous recombination (HR) 
resolution of DSBs [23]. PALB2 also cooperates with RAD51 to trigger strand invasion during 
HR [23]. The many studies reporting the relationship between PALB2 mutation and 
predisposition for development of breast and pancreatic cancers attest to the importance of 
functional PALB2 during DDR [24]. It remains unclear how HIV might utilize PALB2 to 
enhance infectivity. RBBP8 is recruited to DSBs by the DNA repair complex MRN, where it 
cooperates with Sae2 to trigger DNA resection and subsequent RPA coating, a key step in the 
pathway activating ATR and eventual cell cycle arrest [19, 25, 26]. Intriguingly, RBBP8 is also 
known to interact with BRCA1, though it is unclear whether this interaction is necessary for 
RBBP8-mediated ATR activation [19, 27]. The repeated appearance of BRCA1/BRCA2 
interacting proteins in the putative antiviral and susceptibility factors identified in this study 
makes these genes particularly attractive candidates for pursuit in future studies. 
While the results of this study identify novel putative HIV-host interactions, further work 
will be necessary to verify these results. Such future work will include the development of 
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additional CRISPR gRNAs against each of the putative host susceptibility and antiviral factors. 
Since the CRISPR guides used in this study were generated by software that is particularly suited 
to use for large screens, guide specificity and efficiency may not be as high as that of guides 
designed by hand. Additional experiments using bespoke guides may reduce off-target effects 
whilst improving editing efficiency for the target genes, particularly for genes with low editing 
efficiency in this study (table 1, table 2). 
After further verification of the results reported here, follow-up studies will examine the 
mechanisms by which these host susceptibility and antiviral factors influence the HIV life-cycle. 
More specifically, it remains unknown which steps of the HIV life-cycle are modulated by these 
factors; viral entry, reverse transcription, nuclear import, integration, viral capsid assembly, and 
budding are each potentially impacted by these host factors. In addition, these factors may play a 
role in the entry into, maintenance of, or exit from viral latency, the central process governing 
the formation of a permanent viral reservoir within patients and a key hurdle in development of a 
successful HIV cure [28]. Efforts towards the identification of mechanism of action for these 
factors may, therefore, guide future research towards more efficacious treatments or even cures. 
To better examine the importance of these interactions, future experiments will also 
include multiple HIV subtypes. If these interactions are important for the fitness of the virus, it is 
likely that susceptibility factors will be similarly required by other HIV subtypes. In contrast, the 
putative antiviral factors identified in this study may or may not have similar impacts on 
different subtypes of HIV, possibly elucidating previously unknown differences between HIV 
subtype life-cycles. It will also be important to evaluate the impact of these potential differences 
in life-cycle on subtype pathogenicity, an inquiry that will necessitate the evaluation of these 
factors in in vivo systems such as humanized mouse and/or macaque models.  
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Finally, the successful implementation of a CRISPR-based screen for HIV-host 
interactions opens up the potential for similar studies in other viruses. From well-known to 
newly significant viral pathogens, a broad approach such as the one used in this study will allow 
researchers to identify previously unknown interactions. Amongst these interactions we may 
identify potential targets for novel therapeutic drugs, hastening the development of effective 
treatments for diseases both old and new. One advantage of a CRISPR-based screen is the ability 
to investigate indirect interactions, or the factors that contribute to host susceptibility and/or 
antiviral activity after upstream signaling. Assays for direct interactions, such as co-
immunoprecipitation and bioID, are incapable of detecting the factors activated downstream after 
the initial interaction. The fact that a CRISPR-based approach measures the replication 
efficiency of the virus in mutant cells means that it is possible, through this technique, to uncover 
biologically-relevant interactions which might otherwise go undetected. 
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Figures 
 
 
Figure 1. Schematic summarizing the steps followed during performance of the CRISPR screen 
and one-sample T-test analysis of results. 
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Figure 2. Plotted donor 1, day 7 one-sample T-scores for each guide used in the CRISPR screen. 
The >90% and <10% dashed lines represent the cutoffs for top 10% and bottom 10% infectivity 
T-scores respectively. Arrows show example guides targeting putative antiviral and 
susceptibility genes (black font) or control susceptibility genes (red font). 
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Figure 3. Plotted donor 2, day 7 one-sample T-scores for each guide used in the CRISPR screen. 
The >90% and <10% dashed lines represent the cutoffs for top 10% and bottom 10% infectivity 
T-scores respectively. Arrows show example guides targeting putative antiviral and 
susceptibility genes (black font) or control susceptibility genes (red font). 
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Table 1. CRISPR knockout efficiency and <10% one-sample T-test scoring for all ESPL1, 
PALB2, and RBBP8 CRISPR guides. 
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Table 2. CRISPR knockout efficiency and >90% one-sample T-test scoring for all POLG, 
MUTYH, and BRIP1 CRISPR guides. 
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Figure 4. Western blots for identification of suitable polyclonal antibodies targeting POLG, 
BRIP1, MUTYH, ESPL1, and PALB2. No suitable polyclonal antibody for RBBP8 was 
identified during this study. The red boxes identify bands that match the reported molecular 
weights for each protein. 293T cells were transfected with overexpression plasmids for each gene 
prior to lysis and blotting. 
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Figure 5. Western blot validation of shRNA lentiviral vectors for putative antiviral factor 
silencing experiments. 293T cells were transfected with gene overexpression vectors, then 
infected with three pooled shRNA lentiviruses targeting a single gene. This study did not include 
validation experiments for shRNAs targeting putative susceptibility factors. 
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